Literature DB >> 7506924

Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.

C J Fisher1, C E Gillett, B Vojtĕsek, D M Barnes, R R Millis.   

Abstract

The availability of antibodies which recognise p53 protein in paraffin-embedded tissue has created the opportunity to use immunohistochemistry to study the expression of p53 in a wide variety of clinical material. In this paper we have investigated the relationship between the type of fixative and the pattern of p53 staining in mammary carcinoma. Optimal results were obtained from breast tissue fixed in phenol formol saline, methacarn or cold formol saline with positive staining for stabilised p53 protein occurring in 69/95 (73%) cases studied. Care must be taken in the interpretation of these results since positive staining for p53 protein is not always indicative of mutation of the p53 gene. Furthermore, a range of staining patterns is seen in mammary carcinomas, making interpretation difficult. Assessment of staining needs to be standardised in order that different studies can be compared. However, in breast carcinoma, p53 immunohistochemistry appears to give information relating to tumour grade and, independently, to prognosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506924      PMCID: PMC1968757          DOI: 10.1038/bjc.1994.4

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

Review 2.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

3.  p53 mutations occur in aggressive breast cancer.

Authors:  R Mazars; L Spinardi; M BenCheikh; J Simony-Lafontaine; P Jeanteur; C Theillet
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

4.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

Authors:  J Isola; T Visakorpi; K Holli; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

6.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

7.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

8.  Relation between p53 overexpression and established prognostic factors in breast cancer.

Authors:  A M Davidoff; J E Herndon; N S Glover; B J Kerns; J C Pence; J D Iglehart; J R Marks
Journal:  Surgery       Date:  1991-08       Impact factor: 3.982

9.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

10.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

View more
  33 in total

1.  Comparison of different scoring systems for immunohistochemical staining.

Authors:  E J Adams; J A Green; A H Clark; J H Youngson
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

2.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Tissue preparation for immunocytochemistry.

Authors:  J H Williams; B L Mepham; D H Wright
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

4.  Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.

Authors:  F Roberts; A E McCall; R A Burnett
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

5.  [Immunohistochemical expression of p53 protein in squamous epithelial carcinomas and normal and dysplastic epithelium of the mouth cavity].

Authors:  J Piffkó; A Bánkfalvi
Journal:  Mund Kiefer Gesichtschir       Date:  1997-03

6.  p53 Overexpression in laryngeal squamous cell carcinoma and dysplasia.

Authors:  C Barbatis; L Loukas; M Grigoriou; I Nikolaou; A Tsikou-Papafragou; N Marsan; K C Gatter; L Kaklamanis
Journal:  Clin Mol Pathol       Date:  1995-08

Review 7.  P53, apoptosis, and breast cancer.

Authors:  D M Barnes; R S Camplejohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

Review 8.  Molecular staging of head and neck squamous carcinoma.

Authors:  J A Brennan; D Sidransky
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

9.  Predictive Role of p53 Protein as a Single Marker or Associated to Ki67 Antigen in Oral Carcinogenesis.

Authors:  L Montebugnoli; L Felicetti; D B Gissi; F Cervellati; D Servidio; C Marchetti; C Prati; F Flamminio; M P Foschini
Journal:  Open Dent J       Date:  2008-02-21

10.  HPV DNA and p53 alterations in oropharyngeal carcinomas.

Authors:  M Barten; C Ostwald; K Milde-Langosch; P Müller; Y Wukasch; T Löning
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.